key: cord-0806225-fxlqxmci
authors: Mercuro, Nicholas J.; Kenney, Rachel M.; Samuel, Linoj; Tibbetts, Robert J.; Alangaden, George J.; Davis, Susan L.
title: Stewardship opportunities in viral pneumonia: Why not the immunocompromised?
date: 2018-02-26
journal: Transpl Infect Dis
DOI: 10.1111/tid.12854
sha: c876f62d83c9cdf3997ffe0c528e55ba51937f82
doc_id: 806225
cord_uid: fxlqxmci

Antimicrobial management of viral pneumonia has proven to be a challenge in hospitalized immunocompromised patients. A host of factors contribute to the dilemma, such as diagnostic uncertainty, lack of organism identification, and clinical status of the patient. Respiratory virus panel (RVP) use was compared between 131 immunocompromised patients who received send‐out (n = 56) vs in‐house (n = 75) testing. Antimicrobial optimization interventions consisted of antiviral addition/discontinuation, antibiotic discontinuation/de‐escalation, or modification of immunosuppressive regimen. After implementation of an in‐house test with audit and feedback, turnaround time of the RVP was reduced from 46.7 to 5.5 hours (P < .001) and time to intervention was reduced from 52.1 to 13.9 hours (P < .001), yet the frequency of antimicrobial optimization interventions was unchanged (30.7% vs 35.7%). Differences were not observed in duration of empiric antibiotic therapy or length of stay. The overall discontinuation rate for patients tested with a RVP was low (4.6%), and those with positive RVP (n = 43) had antibiotics stopped in 14% of cases. Bacterial pneumonia coinfection was confirmed in 2 patients. Further systematic efforts should be taken to reduce antibiotic use in viral pneumonia and identify the major barriers in the immunocompromised population.

observed over 2 respiratory virus seasons (RVS). Send-out RVP testing was utilized in RVS1 (October 2014-April 2015) without AMS audit. The following year (RVS2, October 2015-April 2016), an in-house RVP that detected 20 respiratory pathogens (BioFire FilmArray RP ® , Salt Lake City, UT, USA) was implemented with concurrent weekday AMS calls to providers. Multidisciplinary education for the use of the in-house RVP was presented and distributed prior to RVS2, and a prospective audit and feedback of RVP results was piloted with rounding pharmacists and the AMS service. The RVP was analyzed in-house from 7 am to 11 pm daily. All transplant patients and patients with immunocompromising conditions in the ICU with respiratory tract infections, tested with a RVP, were included. Pneumonia diagnosis was at the discretion of the critical care or transplant team, as per documentation in progress and discharge summaries. "Immunocompromised" was defined as those with solid organ transplant (SOT), hematopoietic stem cell transplant (HSCT), ANC < 1000 cells/cc, CD4 count < 200 cells/cc, or receiving other immunosuppressive/cytotoxic therapy (alkylating agents, anthracyclines, mTOR and calcineurin inhibitors, thymoglobulin, TNF-alpha inhibitors, CTLA-4 agonists, and corticosteroids equivalent to at least 2 weeks of prednisone 20 mg daily). Patients < 18 years of age, and those who were pregnant or had death or discharge prior to the result of the RVP, were excluded. Time from specimen collection to final result in the electronic medical record was defined as turnaround time. The study was powered to an effect size of 0.5 in turnaround time between RVS1 and RVS2 with a 2-sided alpha of 0.05 and power of 0.80, which yielded a sample size of 176 patients. 5 Outcomes of interest were empiric antimicrobial duration of therapy, hospital length of stay, time to an intervention. Interventions consisted of antimicrobial optimization via de-escalation/discontinuation of antibiotic, initiation/discontinuation of antiviral, or modification of immunosuppressive regimen, beginning from collection of specimen and up to 48 hours following the RVP result. Empiric duration of therapy was defined as antibiotic therapy for pneumonia prior to RVP result and/or targeted therapy interventions. Chisquare was used for categorical variables and Mann-Whitney-U was used for continuous non-parametric variables. Factors associated with antimicrobial optimization were examined in a bivariate analysis. SPSS Version 22 ® was used for statistical analyses.

One hundred thirty-one immunocompromised patients tested with a RVP were analyzed (RVS1, n = 51; RVS2, n = 75). The median age was 60 years and 46.6% of the total population was female. There were no differences in baseline characteristics between RVS1 (send-out testing) and RVS2 (in-house testing) with the exceptions of positive RVP, chronic obstructive pulmonary disease/asthma, and congestive heart failure ( Table 1) . Among 131 patients with immunocompromising factors, renal (18.3%), liver (16.8%), and lung (13%) were the most common types of SOT, while 33 (24.8%) had metastatic cancer, 16 (12%) were on immunosuppressive medications not related to SOT, 7 (5.3%) with HSCT, and 5 (4.5%) had CD4 < 200 cells/cc. Pneumonia was di- to 13.9 hours (P < .001). The in-house RVP did not significantly impact frequency of antimicrobial optimization interventions (30.7% vs 35.7%), but did reduce the time-to-intervention from specimen collection from 52.1 to 13.9 hours (P < .001). There were also no differences between groups for types of intervention (de-escalations Table 2 ).

Rapid diagnostic testing is quickly becoming an influential aspect of stewardship models and has been recommended in practice guidelines for initiating an AMS program. 4 We analyzed 75 immunocompromised patients who were tested with an in-house RVP after AMS implementation, which led to significant reductions in turnaround time and time-to-intervention, and increased diagnostic yield compared to 56 patients with send-out RVP testing. is not yet widely available or practical for all patients and institutions. As RVPs gain popularity in practice, judicious use in patient populations and interpretation of respective results should be taken into higher consideration to optimize antimicrobial management and cost of care. Improved diagnostic yield and turnaround time, which may be a surrogate for ancillary testing and laboratory labor, may still justify RVP use; but will RVPs consistently be used as a de-escalation tool rather than additional academic information?

Further investigation on AMS and resource utilization are warranted in critically ill immunocompromised and transplant patients.

We thank Arin Jantz, PharmD and Zachary Smith, PharmD for their contributions to this study.

O RCI D S.L. Davis http://orcid.org/0000-0001-7521-9486

Solid organ transplant patients: are there opportunities for antimicrobial stewardship?

Community-acquired pneumonia requiring hospitalization among U.S. adults

Impact of antibacterials on subsequent resistance and clinical outcomes in adult patients with viral pneumonia: an opportunity for stewardship

Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America

Antibiotic discontinuation rates associated with positive respiratory viral panel and low procalcitonin results in proven or suspected respiratory infections

Impact of a rapid respiratory panel test on patient outcomes

Clinical and financial benefits of rapid detection of respiratory viruses: an outcomes study

Behavior change strategies to influence antimicrobial prescribing in acute care: a systematic review